U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07334275) titled 'Detection of Minimal Residual Disease Post-prostatectomy' on Dec. 31, 2025.
Brief Summary: The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to more optimal prediction of disease recurrence following radical prostatectomy.
Study Start Date: Sept. 16, 2025
Study Type: OBSERVATIONAL
Condition:
Prostate Cancer
Recruitment Status: RECRUITING
Sponsor: Radboud University Medical Center
Disclaimer: Curated by HT Syndication....